77472 Federal Register / Vol. 85, No. 232 / Wednesday, December 2, 2020 / Notices 

1National HIV Testing Day—June 27, 2019. 

MMWR. 2019;68:561. doi: http://dx.doi.org/ 

10.15585/mmwr.mm6825a1. 2Centers for Disease Control and Prevention. 

Estimated HIV incidence and prevalence in the 

United States, 2014–2018. HIV Surveillance 

Supplemental Report 2020;25(1). Accessed 

September 28, 2020. http://www.cdc.gov/hiv/ 

library/reports/hiv-surveillance.html. 3Harris NS, Johnson AS, Huang YLA, et al. Vital 

Signs: status of human immunodeficiency virus 

testing, viral suppression, and HIV preexposure 

prophylaxis—United States, 2013–2018. MMWR. 

2019;68:1117–1123. doi: http://dx.doi.org/ 

10.15585/mmwr.mm6848e1. 

4Li Z, Purcell DW, Sansom SL, et al. Vital Signs: 

HIV transmission along the continuum of care— 

United States, 2016. MMWR. 2019;68:267–272. 

Figure 1. doi: http://dx.doi.org/10.15585/ 

mmwr.mm6811e1. 

5Harris NS, Johnson AS, Huang YLA, et al. Vital 

Signs: status of human immunodeficiency virus 

testing, viral suppression, and HIV preexposure 

prophylaxis—United States, 2013–2018. MMWR. 

2019;68:1117–1123. doi: http://dx.doi.org/ 

10.15585/mmwr.mm6848e1. 

6Centers for Disease Control and Prevention. HIV 

Surveillance Data Tables (early release): Core 

indicators for monitoring the Ending the HIV 

Epidemic initiative (preliminary data): HIV 

diagnoses and linkage to HIV medical care, 2019 

(reported through December 2019); and preexposure 

prophylaxis (PrEP)—2018, updated. HIV 

Surveillance Data Tables 2020;1(2). Accessed 

October 16, 2020. https://www.cdc.gov/hiv/library/ 

reports/surveillance-data-tables/index.html. 

TABLE 3—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN 1

Activity; 21 CFR section Number of 

respondents 

Number of 

disclosures 

per 

respondent 

Total annual 

disclosures 

Average 

burden per 

disclosure 

Total hours 

Nutrient labeling; §§ 107.10(a) and 107.20 ......................... 5 13 65 8 520 

1There are no capital costs or operating and maintenance costs associated with the information collection. 

We estimate compliance with our 

infant formula labeling requirements in 

§§ 107.10(a) and 107.20 requires 520 

hours annually. 

Dated: November 23, 2020. 

Lauren K. Roth, 

Acting Principal Associate Commissioner for 

Policy. 

[FR Doc. 2020–26537 Filed 12–1–20; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Request for Information: HIV National 

Strategic Plan 2021–2025 Available for 

Public Comment 

AGENCY: Office of the Secretary, 

Department of Health and Human 

Services. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services’ (HHS) Office of 

Infectious Disease and HIV/AIDS Policy 

(OIDP) in the Office of the Assistant 

Secretary for Health (OASH) announces 

the draft HIV National Strategic Plan: A 

Roadmap to End the HIV Epidemic 

(2021–2025) (HIV Plan) available for 

public comment. The draft HIV Plan 

may be reviewed at www.hiv.gov. 

DATES: All comments must be received 

by 5:00 p.m. ET on December 14, 2020 

to be considered. 

ADDRESSES: All comments must be 

submitted electronically to 

HIVPlanComments@hhs.gov to be 

considered. 

FOR FURTHER INFORMATION CONTACT: 

Harold J. Phillips, OIDP, 

Harold.Phillips@hhs.gov, 202–725– 

8872. 

SUPPLEMENTARY INFORMATION: The 

National HIV/AIDS Strategy, first 

released in 2010 and updated in 2015, 

changed the way that Americans talk 

about HIV and the ways that 

stakeholders prioritize and coordinate 

resources and deliver prevention and 

care services that support people with 

HIV or at risk for HIV. As a result, the 

nation’s new HIV infections have 

declined from their peak in the mid1980s—although remaining stable over 

the past decade—and people with HIV 

in care and treatment are living longer, 

healthier lives. In 2018 the estimated 

number of new HIV infections was 

36,400. A robust prevention toolbox that 

includes pre-exposure prophylaxis 

(PrEP), post-exposure prophylaxis 

(PEP), and syringe services programs 

(SSPs) has lowered a person’s risk of 

acquiring HIV. Research in recent years 

has proven that people with HIV who 

take antiretroviral therapy achieve and 

maintain an undetectable viral load, not 

protect their health but also have 

effectively no risk of transmitting HIV 

through sex. 

This stability in the annual number of 

new infections, though, has further 

illuminated opportunities for focused 

efforts. According to the most recent 

available data, less than one-half 

(38.9%) of the U.S. population have 

ever been tested for HIV 1 and an 

estimated 161,800 (14%) people with 

HIV are unaware of their status.2 Only 

63% of people diagnosed with HIV are 

virally suppressed.3 Approximately 

80% of new HIV infections are due to 

people who do not know they have HIV 

or are not receiving regular care,4 and 

only 18% of the approximately 1.2 

million people indicated for PrEP are 

receiving it.5 6

To respond and address the HIV 

public health epidemic, OASH through 

OIDP, in collaboration with a steering 

committee composed of a wide array of 

federal partners, has led and 

coordinated development of the HIV 

Plan. Opportunities for public input 

were provided, and public comments 

received were reviewed and analyzed, 

to help inform development of the 

components of the HIV Plan. The HIV 

Plan covers the entire country, provides 

a roadmap across the federal 

government, non-federal partners and 

stakeholders in all sectors of society, 

and encourages integration of several 

key components that are vital to our 

collective work. 

The HIV Plan is the nation’s third 

consecutive national HIV strategy. It sets 

forth bold targets for ending the HIV 

epidemic in the United States by 2030, 

including a 75% reduction in new HIV 

infections by 2025 and a 90% reduction 

by 2030. The HIV Plan articulates goals, 

objectives, and strategies to prevent new 

infections, treat people with HIV to 

improve health outcomes, reduce HIVrelated disparities, and better integrate 

and coordinate the efforts of all partners 

to end the HIV epidemic in the United 

States. The HIV Plan also establishes 

indicators to measure progress, with 

quantitative targets for each indicator, 

and designates populations 

disproportionately impacted by and at 

risk for HIV as well as key areas of 

focus. 

The order of goals, objectives, and 

strategies does not indicate any 

prioritization, and many are 

intertwined. The following are the HIV 

Plan’s vision and four goals: 

Vision: The United States will be a 

place where new HIV infections are 

prevented, every person knows their 

status, and every person with HIV has 

high-quality care and treatment and 

lives free from stigma and 

discrimination. This vision includes all 

people, regardless of age, sex, gender 

identity, sexual orientation, race, 

Federal Register / Vol. 85, No. 232 / Wednesday, December 2, 2020 / Notices 77473 

1The record is defined in § 207.2(f) of the 

Commission’s Rules of Practice and Procedure (19 

CFR 207.2(f)). 

2 Vice Chair Randolph J. Stayin not participating. 

ethnicity, religion, disability, geographic 

location, or socioeconomic 

circumstance. 

Goals 

1. Prevent new HIV infections; 

2. Increase knoweldge of HIV status; 

3. Reduce HIV-related disparities and 

health inequities; and 

4. Achieve integrated, coordinated 

efforts that adddress the HIV epidemic 

among all partners and stakeholders. 

Information Needs 

The draft HIV Plan may be reviewed 

at: www.hiv.gov. 

OIDP seeks to obtain feedback from 

external stakeholders on the following: 

1. Do the draft plan’s goals, objectives, 

and strategies appropriately address the 

HIV epidemic? 

2. Are there any critical gaps in the 

HIV Plan’s goals, objectives, and 

strategies? If so, please specify the gaps. 

3. Do any of the HIV Plan’s goals, 

objectives and strategies cause concern? 

If so, please specify the goal, objective 

or strategy, and describe the concern 

regarding it. 

Each commenter is limited to a 

maximum of seven pages. 

Authority: 77 FR 15761 (March 16, 2012). 

Dated: November 25, 2020. 

B. Kaye Hayes, 

Acting Director, Office of Infectious Disease 

and HIV/AIDS Policy. 

[FR Doc. 2020–26586 Filed 12–1–20; 8:45 am] 

BILLING CODE 4150–43–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism Initial 

Review Group Neuroscience Review 

Subcommittee. 

Date: March 3, 2021. 

Time: 8:30 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Health, 

National Institute on Alcohol Abuse and 

Alcoholism, 6700 B Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Beata Buzas, Ph.D., 

Scientific Review Officer, Extramural Project 

Review Branch, Office of Extramural 

Activities, National Institute on Alcohol 

Abuse and Alcoholism, 6700B Rockledge 

Drive, Room 2116, MSC 6902, Bethesda, MD 

20892, 301–443–0800, bbuzas@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Clinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training; 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants; 

93.701, ARRA Related Biomedical Research 

and Research Support Awards., National 

Institutes of Health, HHS) 

Dated: November 25, 2020. 

Patricia B. Hansberger, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2020–26561 Filed 12–1–20; 8:45 am] 

BILLING CODE 4140–01–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation Nos. 701–TA–631 and 731– 

TA–1463–1464 (Final)] 

Forged Steel Fittings From India and 

Korea 

Determinations 

On the basis of the record 1 developed 

in the subject investigations, the United 

States International Trade Commission 

(‘‘Commission’’) determines, pursuant 

to the Tariff Act of 1930 (‘‘the Act’’), 

that an industry in the United States is 

materially injured by reason of imports 

of forged steel fittings from India and 

Korea, provided for in subheadings 

7307.92.30, 7307.92.90, 7307.93.30, 

7307.93.60, 7307.93.90, 7307.99.10, 

7307.99.30, and 7307.99.50 of the 

Harmonized Tariff Schedule of the 

United States, that have been found by 

the U.S. Department of Commerce 

(‘‘Commerce’’) to be sold in the United 

States at less than fair value (‘‘LTFV’’), 

and to be subsidized by the government 

of India.2

Background 

The Commission instituted these 

investigations effective October 23, 

2019, following receipt of petitions filed 

with the Commission and Commerce by 

Bonney Forge Corporation (‘‘Bonney’’), 

Mount Union, Pennsylvania, and the 

United Steel, Paper and Forestry, 

Rubber, Manufacturing, Energy, Allied 

Industrial and Service Workers 

International Union (‘‘USW’’), 

Pittsburgh, Pennsylvania. The final 

phase of the investigations was 

scheduled by the Commission following 

notification of preliminary 

determinations by Commerce that 

imports of forged steel fittings from 

India were subsidized within the 

meaning of section 703(b) of the Act (19 

U.S.C. 1671b(b)) and sold at LTFV 

within the meaning of 733(b) of the Act 

(19 U.S.C. 1673b(b)). Notice of the 

scheduling of the final phase of the 

Commission’s investigations and of a 

public hearing to be held in connection 

therewith was given by posting copies 

of the notice in the Office of the 

Secretary, U.S. International Trade 

Commission, Washington, DC, and by 

publishing the notice in the Federal 

Register on June 19, 2020 (85 FR 37109). 

In light of the restrictions on access to 

the Commission building due to the 

COVID–19 pandemic, the Commission 

conducted its hearing through written 

testimony and video conference on 

October 15, 2020. All persons who 

requested the opportunity were 

permitted to participate. 

The Commission made these 

determinations pursuant to §§ 705(b) 

and 735(b) of the Act (19 U.S.C. 

1671d(b) and 19 U.S.C. 1673d(b)). It 

completed and filed its determinations 

in these investigations on November 25, 

2020. The views of the Commission are 

contained in USITC Publication 5137 

(November 2020), entitled Forged Steel 

Fittings from India and Korea: 

Investigation Nos. 701–TA–631 and 

731–TA–1463–1464 (Final). 

By order of the Commission. 

Issued: November 25, 2020. 

Jessica Mullan, 

Attorney Advisor. 

[FR Doc. 2020–26579 Filed 12–1–20; 8:45 am] 

BILLING CODE 7020–02–P